BPA exposure in US-approved levels may alter insulin response in non-diabetic adults

September 13, 2018

In a first study of its kind study, researchers have found that a common chemical consumers are exposed to several times a day may be altering insulin release. Results of the study, led by scientists at the University of Missouri, indicate that the Food and Drug Administration-approved "safe" daily exposure amount of BPA may be enough to have implications for the development of Type 2 diabetes and other metabolic diseases.

"Bisphenol A is an endocrine disrupting chemical that is used to manufacture thermal paper receipts, plastics and a wide range of consumer products," said Frederick vom Saal, an endocrinologist and Curators' Professor in the Division of Biological Sciences in the MU College of Arts and Science, and a co-author on the study. "Experiments with human and mouse pancreatic cells have revealed that low-dose exposure to BPA, in the presence of glucose, triggers an insulin response. We wanted to test the potential effects of BPA in humans to see whether it held true."

In both of the studies, subjects were orally administered a safe dose of BPA, which led to the same amount of BPA in their blood that customers might encounter by handling a cash register receipt; or, the same subjects received a placebo exposure for comparison. Insulin responses were then assessed through an oral glucose tolerance test in the first experiment or a hyperglycemic clamp in the second experiment. Results of both studies showed that BPA altered insulin release relative to the placebo exposure in the subjects. In animal studies repeated BPA exposure resulted in insulin resistance.

"This exploratory study needs to be replicated because it suggests that BPA exposure at a dose considered safe by U.S. regulators could alter glucose-stimulated insulin responses in humans," vom Saal said. "Our study is an initial step toward investigating whether exposure to endocrine disrupting chemicals, such as BPA, contributes to insulin resistance and eventually Type 2 diabetes."
-end-
The study, "Experimental BPA Exposure and Glucose-Stimulated Insulin Response in Adult Men and Women," was published in the Journal of the Endocrine Society. R.W. Stahlhut with the University of Missouri also contributed to the study as first author. Funding was provided by The Passport Foundation and Environmental Health Sciences. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.

University of Missouri-Columbia

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.